Successful Theranostic Application of Somatostatin Receptor Peptides in a Rare Case of Familial Multicentric Paragangliomas

Keywords

SSTR - Familial Paraganglioma - 177Lu-DOTATATE - 68Ga-DOTATOC - PRRT

Publikationsverlauf

Eingereicht: 28. September 2024

Angenommen nach Revision: 17. März 2025

Artikel online veröffentlicht:
26. Mai 2025

• References

• 1 Mete O, Asa SL, Gill AJ. et al. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol 2022; 33 (01) 90-114
• 2 DeLellis RA. Pathology and genetics of tumours of endocrine organs. IARC; 2004.
• 3 Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 1994; 15 (03) 356-368
• 4 Dong X, Meng X, Zhang T. et al. Diagnosis and Outcome of Cardiac Paragangliomas: A Retrospective Observational Cohort Study in China. Front Cardiovasc Med 2021; 8
• 5 Szymańska A, Szymański M, Czekajska-Chehab E. et al. Diagnosis and management of multiple paragangliomas of the head and neck. Eur Arch Otorhinolaryngol 2015; 272 (08) 1991-1999
• 6 Puliani G, Sesti F, Feola T. et al. Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family. Journal of Clinical Medicine 2020; 9 (02) 588
• 7 Carrión A, Mauri M, Yuste A. Late diagnosis of an index case of SDH-related paraganglioma/pheochromocytoma syndrome. Endocrinologia y Nutricion: Organo de la Sociedad Espanola de Endocrinologia y Nutricion 2011; 59 (02) 148-150
• 8 Lodish MB, Adams KT, Huynh TT. et al. Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl. Endocr Relat Cancer 2010; 17 (03) 581-588
• 9 Al-Ibraheem A, Zimmermann R, Abdlkadir AS. et al. Radiotheranostics Global Market and Future Developments. Semin Nucl Med 2024;
• 10 Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E. et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clinical and Translational Oncology 2021; 23 (10) 1995-2019
• 11 Strosberg JR, Caplin ME, Kunz PL. et al. ¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology 2021; 22 (12) 1752-1763
• 12 Łoń I, Kunikowska J, Jędrusik P. et al. Familial SDHB gene mutation in disseminated non-hypoxia-related malignant paraganglioma treated with [90Y] Y/[¹⁷⁷Lu] Lu-DOTATATE. Intractable & Rare Diseases Research 2021; 10 (03) 207-213